Pasithea Therapeutics Corp. Common Stock
KTTAPasithea Therapeutics Corp. is a biotechnology company focused on developing novel therapies for psychiatric and neurological disorders. The company specializes in psychedelic and psychoplastogenic compounds, aiming to create innovative treatments for conditions such as depression, anxiety, and related mental health issues. Pasithea combines scientific research with clinical development to advance its therapeutic pipeline.
Company News
Pasithea Therapeutics raised $60 million through a public offering of 80 million shares at $0.75 per share, led by healthcare investors. The proceeds will support ongoing research and extend the company's cash runway through the first half of 2028.
Pasithea Therapeutics reported positive pharmacokinetic data for its PAS-004 tablet in a Phase 1/1b trial for neurofibromatosis type 1 (NF1) patients, demonstrating linear dose-proportionality and improved tablet formulation characteristics.
The neurofibromatosis type 1 market is expected to grow significantly due to advances in treatment, increased diagnoses, and ongoing clinical trials. Unmet needs in adult populations and systemic disease management create opportunities for new entrants and differentiated strategies.
Pasithea Therapeutics, a clinical-stage biotechnology company, announced the closing of a $5 million public offering to fund its ongoing research, clinical trials, and corporate initiatives.
Pasithea Therapeutics, a clinical-stage biotechnology company, announced that its Vice President of Business Development, Mathew Lazarus, will be presenting at the 2025 CAGLA NeauxCancer Conference in New Orleans. The presentation will provide an overview of Pasithea's next-generation macrocyclic MEK inhibitor, PAS-004, and the company's progress...
